CA2295076A1 - New combination of antiasthma medicaments - Google Patents
New combination of antiasthma medicaments Download PDFInfo
- Publication number
- CA2295076A1 CA2295076A1 CA002295076A CA2295076A CA2295076A1 CA 2295076 A1 CA2295076 A1 CA 2295076A1 CA 002295076 A CA002295076 A CA 002295076A CA 2295076 A CA2295076 A CA 2295076A CA 2295076 A1 CA2295076 A1 CA 2295076A1
- Authority
- CA
- Canada
- Prior art keywords
- active ingredient
- rofleponide
- composition
- solvate
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a composition or kit having as a first active ingredient formoterol, or a salt or solvate derivative thereof, and having as a second active ingredient ropfleponide, or a fatty acid ester thereof. Also disclosed are methods for treating respiratory disorders using this composition or kit.
Description
NEW COMBINATION OF ANTIASTHMA MEDICAMENTS
Field of the Invention The present invention relates to compositions and methods useful in the treatment of s respiratory disorders, particularly asthma.
Background of the Invention Despite recent advances in the awareness of asthma and the introduction of powerful and effective anti-asthma drugs, asthma remains a poorly understood and frequently poorly ~o treated disease. There have been recent advances in the treatment of the disease which result from the recognition that asthma is a chronic inflammatory disease.
Therapy is now aimed at both controlling the symptoms and reducing the inflammation. The symptoms include uncontrolled airway inflammation which may lead to mucosal damage and structural changes possibly leading to irreversible narrowing of the airways and fibrosis of ~ s the lungs.
The symptoms may be controlled by ~i2-adrenoreceptor agonists such as salbutamol, bambuterol, clenbuterol, fenoterol, procaterol, bitolterol, broxaterol, salmeterol, terbutaline and formoterol.
Prophylactic therapy is typically provided by steroids such as beclomethasone zo dipropionate (BDP), beclomethasone monopropionate (BMP), flunisolide, triamcinolone acetonide, dexamethasone, tipredane, ciclesonid, momethasone, RPR 106541, fluticasone or fluticasone propionate and budesonide or by way of sodium cromoglycate or nedocromil sodium.
Summary of the Invention The invention is based on the discovery that formeterol and rofleponide esters, or their salts or solvates, when administered to a patient either concurrently or sequentially, are unexpectedly effective in treating respiratory disorders involving inflammation, such as s asthma. Accordingly, the invention features a composition having, in an admixture: (a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt; and (b) a second active ingredient which is rofleponide or a fatty acid ester of rofleponide.
It is preferred that the molar ratio of (a) to (b} is from 1:1 to 1:100, preferably from 1:1 ~o to 1:60, more preferably from 1:1 to 1:3~, and most preferably from 1:16.
The first active ingredient (a) of the composition can be, for example, formoterol ftunarate dihydrate, and the second active ingredient (b) of the composition can be, for example, rofleponide palmitate.
The composition can be provided in the form of a dry powder, the particles of which is may have a mass median diameter of less than 10~m.
The invention also includes a kit containing: (a) a vessel containing a first active ingredient that is formoterol, a pharmaceutically acceptable salt- or solvate thereof, or a solvate of such a salt; (b) a vessel containing a second active ingredient that is either rofleponide or a fatty acid ester of rofleponide; and (c) instructions for the sequential or 2o simultaneous administration of the first and second active ingredients to a patient in need thereof.
A patient suffering from a respiratory disorder such as asthma can be treated by administering (e.g., via inhalation), simultaneously or sequentially, (a) a dose of a first active ingredient selected from the group consisting of formoterol, a pharmaceutically is acceptable salt or solvate thereof, and a solvate of such a salt; and (b) a dose of a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide. The active ingredients can be provided to the patient for inhalation in dry powder form.
When administered sequentially, the active ingredients can be administered in either 30 order, and within a two-hour time period. For example, the first active ingredient can be administered to the patient less than about 30 minutes after the second active ingredient, or the second active ingredient can be administered to the patient less than about 30 minutes after the first active ingredient.
Other features and advantages of the invention will be apparent from the following s description of the preferred embodiments thereof, and from the claims.
The combination according to the invention has the advantage that the toal dose of each active ingredient can be decreased and is more likely to provide patient compliance then would be extected from the properties of the individual active ingredients.
~o Detailed Description The invention provides a composition having (a) a first active ingredient selected from the group consisting of formoterol, a pharmaceutically acceptable salt or solvate of formoterol, and a solvate of such a salt; (b) a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide; and, optionally, (c) ~s one or more pharmaceutically acceptable additives, diluents or carriers.
It has been found, using a sephadex-induced edema model (Kallstrom et al., Agents and Action 17:355-377 (1985)), that the combination of active ingredients provides a significantly enhanced anti-inflammatory effect compared to the sum of the individual anti-inflammatory effects of the two active ingredients, thus providing a significant advantage.
2o The first and second active ingredients of the composition can be administered simultaneously or sequentially to treat respiratory disorders. By simultaneous is meant that the first and second active ingredients (a) and (b) are administered concomitantly, for example as an admixture. Sequential administration generally comprises administering one immediately after the other. They still have the desired effect if they are administered 2s separately but not more than about two hours apart, for example no more than 30 minutes and preferably no more than 5 minutes apart.
Preferably the composition is administered to provide a daily dose of from 0.5 to 200 nmol (preferably from 4 to 100 nmol) of (a) and from 0.5 to 1140 nmol (preferably 14 to 285 nmol and more preferably from 14 to 285 nmol) of (b) 30 (subject to the molar ratio of (a) to (b) being from 1:1 to 1:100).
When (a) is fonnoterol fumarate dihydrate, the preferred daily dose is from 0.2 to 84 p.g (preferably from 2 to 42 p.g) of (a), and from 0.4 to 800 p.g (preferably from 10 to 400 p.g, more preferably from 10 to 200 p.g) of (b} where (b) is rofleponide palmitate (subject to the molar ratio of (a) to (b) being within the range of from 1:1 to 1:100).
Suitable physiologically acceptable salts of formoterol include acid addition salts derived from inorganic and organic acids, for example the chloride, bromide, sulphate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricarballylate, hydroxynaphthalene-io carboxylate or oleate salts or solvates thereof. Active ingredient (a) is preferably formoterol fumarate, especially as the dihydrate.
Rofleponide is preferably esterified by a palmitoyl group.
Preferably each of the active ingredients comprises one or more pharmaceutically acceptable additives, diluents or carriers, more preferably in an amount of from 50 to 2000 ~s ~g in a daily dose, most preferably in an amount of from 100 to 1000 p.g.
Examples of suitable diluents or Garners include lactose, dextran, mannitol and glucose.
Preferably lactose is used.
Since active ingredient (b) is preferably a fatty acid ester, formulations containing it are desirably liposomal or proliposomal if they are dry powder formulations.
Suitable zo proliposomal formulations of fatty acid esters of rofleponide are described in WO
96/19199. For improved stability the formulation may comprise tocopherol, especially a-tocopherol.
Active ingredients (a) and (b) may optionally be formulated together to be administered simultaneously. For example, they may be formulated in admixture as a is proliposomal powder, for example of the general type described in WO
(preferably containing tocopherol as a stabilizing agent) or as an intimate mixture of {a) in the form of a dry powder and a proliposomal dry powder containing (b).
One or more of the active ingredients according to the invention are preferably in the form of a dry powder, more preferably a micronised dry powder, e.g. having a mass 3o median diameter of less than IOpm, for example from 1 to Spm, most preferably an agglomerated micronised dry powder. Alternatively active ingredient (a) may be in the form of an ordered mixture with ingredient (c). The ingredients used in the invention can be obtained in these preferred forms using methods known to those of skill in the art.
The invention further provides a method of treating a respiratory disorder, which is s preferably asthma, chronic obstructive pulmonary disease (COPD) and/or rhinitis, which method comprises applying to a patient suffering from, or liable to suffer from, such a disorder a therapeutically effective amount of a combination according to the invention.
According to the invention there is further provided the use of an admixture or kit according to the invention in the manufacture of a medicament for simultaneous, separate ~o or sequential use in therapy, preferably in the treatment of a respiratory disorder, e.g.
asthma, chronic obstructive pulmonary disease (COPD) and/or rhinitis.
Administration may be by inhalation orally or intranasally. The ingredients are preferably adapted to be administered from a dry powder inhaler.
The combination may optionally be administered as divided doses from 1 to 4, and ~s preferably once or twice a day, which means unit doses from 0.05 pg to 84 pg (preferably from 0.5 p,g to 42 fig) of formoterol fumarate dihydrate and from 0.1 ug to 800 ug (preferably from 2.5 ~g to 400 p.g) of rofleponide pahnitate.
Example 1 zo Rofleponide palmitate (IO parts by weight), dipalmitoylphosphatidylcholine (63 parts), dimyristoylphosphatidylcholine (24 parts), sodium dipalmitoylphosphatidylglycerol (3 parts) and racemic a-tocopherol (0.1 part) were dissolved in tertiary butanol (1300 parts) at 80°C. The solution was poured onto the shelves of a freeze-dryer cooled to -35°C. The solution had reached this temperature after about 30 minutes, the pressure in the freeze-zs dryer was then reduced in order to induce sublimation of the solvent. While the rate of sublimation could be adjusted by decreasing the pressure and increasing the temperature, the temperature throughtout the process was not allowed to exceed -10°C. Freeze-drying was continued until all the solvent had been removed. The resulting powder was scraped from the shelves of the freeze-dryer and passed through a sieve. This powder was 3o micronised in an air jet mill to a powder particle size of less than 5 Vim.
0.5 parts of formoterol fumarate dihydrate was mixed with 79.5 parts of lactose monohydrate. The blend was micronised using a high pressure air jet mill and then conditioned using the process of EP-A-717 616. This mixture (80 parts) was added to the steroid/lipid powder mixture (20 parts) by mixing and homogenising with a low pressure s jet mill. The mixture was then spheronised using the process of EP-A-721 331 and filled into a blister, a capsule or a storage chamber of an inhaler for use in a dry powder inhaler.
Other Embodiments It is to be understood that while the invention has been described in conjunction with io the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims.
Other aspects, advantages, and modifications are within the scope of the following claims.
Field of the Invention The present invention relates to compositions and methods useful in the treatment of s respiratory disorders, particularly asthma.
Background of the Invention Despite recent advances in the awareness of asthma and the introduction of powerful and effective anti-asthma drugs, asthma remains a poorly understood and frequently poorly ~o treated disease. There have been recent advances in the treatment of the disease which result from the recognition that asthma is a chronic inflammatory disease.
Therapy is now aimed at both controlling the symptoms and reducing the inflammation. The symptoms include uncontrolled airway inflammation which may lead to mucosal damage and structural changes possibly leading to irreversible narrowing of the airways and fibrosis of ~ s the lungs.
The symptoms may be controlled by ~i2-adrenoreceptor agonists such as salbutamol, bambuterol, clenbuterol, fenoterol, procaterol, bitolterol, broxaterol, salmeterol, terbutaline and formoterol.
Prophylactic therapy is typically provided by steroids such as beclomethasone zo dipropionate (BDP), beclomethasone monopropionate (BMP), flunisolide, triamcinolone acetonide, dexamethasone, tipredane, ciclesonid, momethasone, RPR 106541, fluticasone or fluticasone propionate and budesonide or by way of sodium cromoglycate or nedocromil sodium.
Summary of the Invention The invention is based on the discovery that formeterol and rofleponide esters, or their salts or solvates, when administered to a patient either concurrently or sequentially, are unexpectedly effective in treating respiratory disorders involving inflammation, such as s asthma. Accordingly, the invention features a composition having, in an admixture: (a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt; and (b) a second active ingredient which is rofleponide or a fatty acid ester of rofleponide.
It is preferred that the molar ratio of (a) to (b} is from 1:1 to 1:100, preferably from 1:1 ~o to 1:60, more preferably from 1:1 to 1:3~, and most preferably from 1:16.
The first active ingredient (a) of the composition can be, for example, formoterol ftunarate dihydrate, and the second active ingredient (b) of the composition can be, for example, rofleponide palmitate.
The composition can be provided in the form of a dry powder, the particles of which is may have a mass median diameter of less than 10~m.
The invention also includes a kit containing: (a) a vessel containing a first active ingredient that is formoterol, a pharmaceutically acceptable salt- or solvate thereof, or a solvate of such a salt; (b) a vessel containing a second active ingredient that is either rofleponide or a fatty acid ester of rofleponide; and (c) instructions for the sequential or 2o simultaneous administration of the first and second active ingredients to a patient in need thereof.
A patient suffering from a respiratory disorder such as asthma can be treated by administering (e.g., via inhalation), simultaneously or sequentially, (a) a dose of a first active ingredient selected from the group consisting of formoterol, a pharmaceutically is acceptable salt or solvate thereof, and a solvate of such a salt; and (b) a dose of a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide. The active ingredients can be provided to the patient for inhalation in dry powder form.
When administered sequentially, the active ingredients can be administered in either 30 order, and within a two-hour time period. For example, the first active ingredient can be administered to the patient less than about 30 minutes after the second active ingredient, or the second active ingredient can be administered to the patient less than about 30 minutes after the first active ingredient.
Other features and advantages of the invention will be apparent from the following s description of the preferred embodiments thereof, and from the claims.
The combination according to the invention has the advantage that the toal dose of each active ingredient can be decreased and is more likely to provide patient compliance then would be extected from the properties of the individual active ingredients.
~o Detailed Description The invention provides a composition having (a) a first active ingredient selected from the group consisting of formoterol, a pharmaceutically acceptable salt or solvate of formoterol, and a solvate of such a salt; (b) a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide; and, optionally, (c) ~s one or more pharmaceutically acceptable additives, diluents or carriers.
It has been found, using a sephadex-induced edema model (Kallstrom et al., Agents and Action 17:355-377 (1985)), that the combination of active ingredients provides a significantly enhanced anti-inflammatory effect compared to the sum of the individual anti-inflammatory effects of the two active ingredients, thus providing a significant advantage.
2o The first and second active ingredients of the composition can be administered simultaneously or sequentially to treat respiratory disorders. By simultaneous is meant that the first and second active ingredients (a) and (b) are administered concomitantly, for example as an admixture. Sequential administration generally comprises administering one immediately after the other. They still have the desired effect if they are administered 2s separately but not more than about two hours apart, for example no more than 30 minutes and preferably no more than 5 minutes apart.
Preferably the composition is administered to provide a daily dose of from 0.5 to 200 nmol (preferably from 4 to 100 nmol) of (a) and from 0.5 to 1140 nmol (preferably 14 to 285 nmol and more preferably from 14 to 285 nmol) of (b) 30 (subject to the molar ratio of (a) to (b) being from 1:1 to 1:100).
When (a) is fonnoterol fumarate dihydrate, the preferred daily dose is from 0.2 to 84 p.g (preferably from 2 to 42 p.g) of (a), and from 0.4 to 800 p.g (preferably from 10 to 400 p.g, more preferably from 10 to 200 p.g) of (b} where (b) is rofleponide palmitate (subject to the molar ratio of (a) to (b) being within the range of from 1:1 to 1:100).
Suitable physiologically acceptable salts of formoterol include acid addition salts derived from inorganic and organic acids, for example the chloride, bromide, sulphate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricarballylate, hydroxynaphthalene-io carboxylate or oleate salts or solvates thereof. Active ingredient (a) is preferably formoterol fumarate, especially as the dihydrate.
Rofleponide is preferably esterified by a palmitoyl group.
Preferably each of the active ingredients comprises one or more pharmaceutically acceptable additives, diluents or carriers, more preferably in an amount of from 50 to 2000 ~s ~g in a daily dose, most preferably in an amount of from 100 to 1000 p.g.
Examples of suitable diluents or Garners include lactose, dextran, mannitol and glucose.
Preferably lactose is used.
Since active ingredient (b) is preferably a fatty acid ester, formulations containing it are desirably liposomal or proliposomal if they are dry powder formulations.
Suitable zo proliposomal formulations of fatty acid esters of rofleponide are described in WO
96/19199. For improved stability the formulation may comprise tocopherol, especially a-tocopherol.
Active ingredients (a) and (b) may optionally be formulated together to be administered simultaneously. For example, they may be formulated in admixture as a is proliposomal powder, for example of the general type described in WO
(preferably containing tocopherol as a stabilizing agent) or as an intimate mixture of {a) in the form of a dry powder and a proliposomal dry powder containing (b).
One or more of the active ingredients according to the invention are preferably in the form of a dry powder, more preferably a micronised dry powder, e.g. having a mass 3o median diameter of less than IOpm, for example from 1 to Spm, most preferably an agglomerated micronised dry powder. Alternatively active ingredient (a) may be in the form of an ordered mixture with ingredient (c). The ingredients used in the invention can be obtained in these preferred forms using methods known to those of skill in the art.
The invention further provides a method of treating a respiratory disorder, which is s preferably asthma, chronic obstructive pulmonary disease (COPD) and/or rhinitis, which method comprises applying to a patient suffering from, or liable to suffer from, such a disorder a therapeutically effective amount of a combination according to the invention.
According to the invention there is further provided the use of an admixture or kit according to the invention in the manufacture of a medicament for simultaneous, separate ~o or sequential use in therapy, preferably in the treatment of a respiratory disorder, e.g.
asthma, chronic obstructive pulmonary disease (COPD) and/or rhinitis.
Administration may be by inhalation orally or intranasally. The ingredients are preferably adapted to be administered from a dry powder inhaler.
The combination may optionally be administered as divided doses from 1 to 4, and ~s preferably once or twice a day, which means unit doses from 0.05 pg to 84 pg (preferably from 0.5 p,g to 42 fig) of formoterol fumarate dihydrate and from 0.1 ug to 800 ug (preferably from 2.5 ~g to 400 p.g) of rofleponide pahnitate.
Example 1 zo Rofleponide palmitate (IO parts by weight), dipalmitoylphosphatidylcholine (63 parts), dimyristoylphosphatidylcholine (24 parts), sodium dipalmitoylphosphatidylglycerol (3 parts) and racemic a-tocopherol (0.1 part) were dissolved in tertiary butanol (1300 parts) at 80°C. The solution was poured onto the shelves of a freeze-dryer cooled to -35°C. The solution had reached this temperature after about 30 minutes, the pressure in the freeze-zs dryer was then reduced in order to induce sublimation of the solvent. While the rate of sublimation could be adjusted by decreasing the pressure and increasing the temperature, the temperature throughtout the process was not allowed to exceed -10°C. Freeze-drying was continued until all the solvent had been removed. The resulting powder was scraped from the shelves of the freeze-dryer and passed through a sieve. This powder was 3o micronised in an air jet mill to a powder particle size of less than 5 Vim.
0.5 parts of formoterol fumarate dihydrate was mixed with 79.5 parts of lactose monohydrate. The blend was micronised using a high pressure air jet mill and then conditioned using the process of EP-A-717 616. This mixture (80 parts) was added to the steroid/lipid powder mixture (20 parts) by mixing and homogenising with a low pressure s jet mill. The mixture was then spheronised using the process of EP-A-721 331 and filled into a blister, a capsule or a storage chamber of an inhaler for use in a dry powder inhaler.
Other Embodiments It is to be understood that while the invention has been described in conjunction with io the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims.
Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (17)
1. A therapeutic composition comprising, in admixture:
(a) a first active ingredient selected from the group consisting of formoterol, a pharmaceutically acceptable salt or solvate thereof, and a solvate of such a salt; and (b) a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide, wherein the molar ratio of (a) to (b) in the composition is from 1:1 to 1:100.
(a) a first active ingredient selected from the group consisting of formoterol, a pharmaceutically acceptable salt or solvate thereof, and a solvate of such a salt; and (b) a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide, wherein the molar ratio of (a) to (b) in the composition is from 1:1 to 1:100.
2. The composition of claim 1, wherein the molar ratio of (a) to (b) in the composition is from 1:1 to 1:60, preferably from 1:1 to 1:35.
3. The composition of claim 1 or 2, wherein (a) is formoterol fumarate dihydrate.
4. The composition of any one of claims 1 to 3, wherein (b) is rofleponide palmitate.
5. The composition of any one of claims 1 to 4, additionally comprising a pharmaceutically acceptable additive, diluent or carrier suitable for inhalation.
6. The composition of any one of claims 1 to 5, in the form of a dry powder the particles of which have a mass median diameter of less than 10 µm.
7. A kit comprising (a) a vessel containing a first active ingredient selected from the group consisting of formoterol, a pharmaceutically acceptable salt or solvate thereof, and a solvate of such a salt;
(b) a vessel containing a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide; and (c) instructions for the sequential or simultaneous administration of the first and second active ingredients to a patient in need thereof, said instructions specifying that the first and second active ingredients be administered in a molar ratio ranging from 1:1 to 1:100.
(b) a vessel containing a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide; and (c) instructions for the sequential or simultaneous administration of the first and second active ingredients to a patient in need thereof, said instructions specifying that the first and second active ingredients be administered in a molar ratio ranging from 1:1 to 1:100.
8. The kit of claim 7, wherein the first active ingredient is formoterol fumarate dihydrate.
9. The kit of claim 7 or 8, wherein the second active ingredient is rofleponide palmitate.
10. The kit of any one of claims 7 to 9, wherein the instructions specify that the first and second active ingredients be administered in a molar ratio ranging from 1:1 to 1:60, preferably from 1:1 to 1:35.
11. A method of treating a respiratory disorder, which method comprises simultaneously or sequentially administering to a patient suffering from the disorder (a) a dose of a first active ingredient selected from the group consisting of formoterol, a pharmaceutically acceptable salt or solvate thereof, and a solvate of such a salt; and (b) a dose of a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide, wherein the molar ratio of (a) to (b) is from 1:1 to 1:100.
12. The method of claim 11, wherein the molar ratio of (a) to (b) is from 1:1 to 1:60, preferably from 1:1 to 1:35.
13. The method of claim 11 or 12, wherein the first active ingredient is formoterol fumarate dihydrate.
14. The method of any one of claims 11 to 13, wherein the second active ingredient is rofleponide palmitate.
15. The method of any one of claims 11 to 14, wherein the first active ingredient is administered to the patient less than about 30 minutes before and after the second active ingredient.
16. The method of any one of claims 11 to 15, wherein the doses are administered to the patient by causing the patient to inhale them simultaneously.
17. The method of claim 16, wherein the first and second active ingredients are both provided to the patient for inhalation in dry powder form.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88382397A | 1997-06-27 | 1997-06-27 | |
| US08/883,823 | 1997-06-27 | ||
| PCT/SE1998/001089 WO1999000134A1 (en) | 1997-06-27 | 1998-06-08 | New combination of antiasthma medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2295076A1 true CA2295076A1 (en) | 1999-01-07 |
Family
ID=25383399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002295076A Abandoned CA2295076A1 (en) | 1997-06-27 | 1998-06-08 | New combination of antiasthma medicaments |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1009408A1 (en) |
| JP (1) | JP2002510310A (en) |
| KR (1) | KR20010014162A (en) |
| AU (1) | AU8135098A (en) |
| BR (1) | BR9810452A (en) |
| CA (1) | CA2295076A1 (en) |
| EE (1) | EE9900594A (en) |
| HU (1) | HUP0002533A3 (en) |
| ID (1) | ID24063A (en) |
| IL (1) | IL133597A0 (en) |
| IS (1) | IS5303A (en) |
| NO (1) | NO996438L (en) |
| PL (1) | PL337722A1 (en) |
| SK (1) | SK184799A3 (en) |
| TR (1) | TR199903272T2 (en) |
| WO (1) | WO1999000134A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9703407D0 (en) | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| SE9802073D0 (en) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| GB9912639D0 (en) | 1999-05-28 | 1999-07-28 | Britannia Pharmaceuticals Ltd | Improvements in and relating to treatment of respiratory conditions |
| SE9900833D0 (en) * | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
| GB0009607D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medical compositions |
| GB0009617D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| AU2003263717A1 (en) * | 2002-09-25 | 2004-04-19 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9302777D0 (en) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| WO1993011773A1 (en) * | 1991-12-18 | 1993-06-24 | Aktiebolaget Astra | New combination of formoterol and budesonide |
| AR002009A1 (en) * | 1994-12-22 | 1998-01-07 | Astra Ab | PHARMACEUTICAL COMPOSITION, PROCEDURE FOR THE MANUFACTURE OF A PROLIPOSOMA POWDER AS USED IN SUCH COMPOSITION, PROCEDURE FOR LAMANUFACTURE OF SUCH COMPOSITION, USE OF SUCH PHARMACEUTICAL COMPOSITION IN THE MANUFACTURE OF A DISPOSAL MEDICINAL PRODUCT. |
| SE9501384D0 (en) * | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| SE9603669D0 (en) * | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
-
1998
- 1998-06-08 CA CA002295076A patent/CA2295076A1/en not_active Abandoned
- 1998-06-08 IL IL13359798A patent/IL133597A0/en unknown
- 1998-06-08 SK SK1847-99A patent/SK184799A3/en unknown
- 1998-06-08 PL PL98337722A patent/PL337722A1/en unknown
- 1998-06-08 AU AU81350/98A patent/AU8135098A/en not_active Abandoned
- 1998-06-08 ID IDW991684A patent/ID24063A/en unknown
- 1998-06-08 EE EEP199900594A patent/EE9900594A/en unknown
- 1998-06-08 TR TR1999/03272T patent/TR199903272T2/en unknown
- 1998-06-08 EP EP98931163A patent/EP1009408A1/en not_active Withdrawn
- 1998-06-08 JP JP50547999A patent/JP2002510310A/en active Pending
- 1998-06-08 KR KR1019997012233A patent/KR20010014162A/en not_active Application Discontinuation
- 1998-06-08 WO PCT/SE1998/001089 patent/WO1999000134A1/en not_active Application Discontinuation
- 1998-06-08 HU HU0002533A patent/HUP0002533A3/en unknown
- 1998-06-08 BR BR9810452-7A patent/BR9810452A/en not_active IP Right Cessation
-
1999
- 1999-12-15 IS IS5303A patent/IS5303A/en unknown
- 1999-12-23 NO NO996438A patent/NO996438L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO996438L (en) | 2000-02-28 |
| EE9900594A (en) | 2000-08-15 |
| HUP0002533A3 (en) | 2001-03-28 |
| TR199903272T2 (en) | 2000-08-21 |
| EP1009408A1 (en) | 2000-06-21 |
| ID24063A (en) | 2000-07-06 |
| AU8135098A (en) | 1999-01-19 |
| NO996438D0 (en) | 1999-12-23 |
| BR9810452A (en) | 2000-09-05 |
| SK184799A3 (en) | 2000-06-12 |
| JP2002510310A (en) | 2002-04-02 |
| KR20010014162A (en) | 2001-02-26 |
| PL337722A1 (en) | 2000-08-28 |
| IS5303A (en) | 1999-12-15 |
| HUP0002533A2 (en) | 2000-12-28 |
| IL133597A0 (en) | 2001-04-30 |
| WO1999000134A1 (en) | 1999-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU715319B2 (en) | New combination | |
| AU673660C (en) | New combination of formoterol and budesonide | |
| US8461211B2 (en) | Use for budesonide and formoterol | |
| EP1085877B1 (en) | Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma | |
| JP3042867B2 (en) | Respiratory disease drug | |
| EP1007017A1 (en) | New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof | |
| CA2295076A1 (en) | New combination of antiasthma medicaments | |
| WO2000053188A1 (en) | New combination of r,r-formoterol and budesonide in a pharmaceutical composition useful for treating respiratory disorders, such as asthma, rhinitis and copd | |
| EP1101493A2 (en) | New combination of formoterol and budesonide | |
| MXPA99011676A (en) | New combination of antiasthma medicaments | |
| CZ466899A3 (en) | Novel combination of anti-asthmatic medicaments | |
| MXPA98004357A (en) | New combination | |
| MXPA00011806A (en) | Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |